- Presence of HPV-16/18 with baseline negative intraepithelial lesions or malignancy (NILM) indicates significantly elevated future risk for high-grade cervical intraepithelial neoplasia grade 2 (CIN2+) or higher, especially in women
- Increased risk seen with all subtypes in women >30 years.
Why this matters
- Consider risk stratification genotyping for HPV-16/18 in women
- 96 cases, 480 controls (5/case).
- 45.8% (n=44) cases diagnosed with CIN2; 54.2% (n=52) developed CIN3 or higher.
- In women >30 years, both baseline positive HPV-16/18 (OR, 8.16; 95% CI, 3.28-20.3) and other HPV types (OR, 9.04; 95% CI, 3.42-23.9) significantly increased future CIN2+ risk. Corresponding future CIN3+ risk: HPV-16/18 (OR, 17.8; 95% CI, 3.84-82.9), other HPV (OR, 7.12; 95% CI, 2.05-24.8).
- Nested, case-control study examining association of negative NILM and CIN2+ development 9 years later.
- Funding: Swedish Cancer Foundation, others.
- False negatives.
- HPV follow-up data lacking.
- Controls CIN status inferred.